ArticleTheranostics2019
An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Optogenetics for Investigating and Targeting Hallmark Traits of Cancer.Biomolecules · 2026Review
- Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025Review
- Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics.Cardiovascular research · 2025Review
- Optogenetic engineering for precision cancer immunotherapy.Trends in pharmacological sciences · 2025Review
- Bioengineered therapeutic systems for improving antitumor immunity.National science review · 2025Review
- Ultrasound-mediated spatial and temporal control of engineered cells in vivo.Nature communications · 2024Article
- Reshaping tumor microenvironment by regulating local cytokines expression with a portable smart blue-light controlled device.Communications biology · 2024Article
- Development of an optogenetics tool, Opto-RANK, for control of osteoclast differentiation using blue light.Scientific reports · 2024Article
- Emerging optogenetics technologies in biomedical applications.Smart medicine · 2023Review
- Light-inducible T cell engagers trigger, tune, and shape the activation of primary T cells.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies.Cancer immunology research · 2023Article
- Review
- Optical sensing and control of T cell signaling pathways.Frontiers in physiology · 2023Review
- Recent progress of gene circuit designs in immune cell therapies.Cell systems · 2022Review
- Optophysiology: Illuminating cell physiology with optogenetics.Physiological reviews · 2022Review
- Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.Frontiers in oncology · 2022Review
- Engineering Supramolecular Organizing Centers for Optogenetic Control of Innate Immune Responses.Advanced biology · 2021Article
- Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy.Vaccines · 2020Review
- Optogenetic approaches to control CaCurrent opinion in physiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Bixing ZhaoThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Yingchao WangThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Xionghong TanThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Xiaoyuan ZhengThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Fei WangThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Kun KeThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Cuilin ZhangThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Naishun LiaoThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Yuan DangDepartment of Comparative, Fuzhou General Hospital, Xiamen University Medical College, 156 Road Xi'erhuanbei, Fuzhou 350025, Fujian, P.R. China.
Yingjun ShiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Youshi ZhengThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Yunzhen GaoThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Qin LiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Xiaolong LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Jingfeng LiuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
Fujian Medical University · CNMengchao Hepatobiliary Hospital · CNFirst Affiliated Hospital of Fujian Medical University · CNFujian Agriculture and Forestry University · CNXiamen University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCarcinoma, HepatocellularCell LineCell Line, TumorCytokinesDisease Models, AnimalHEK293 CellsHeLa CellsHep G2 CellsHumansImmunologic FactorsImmunotherapyLiver NeoplasmsLymphocyte ActivationMiceMice, Inbred NODCytokinesImmunologic Factorsengineered T cellshepatocellular carcinomaimmune cell therapyoptogenetics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.